Danaher acquires Precision NanoSystems

By The Science Advisory Board staff writers

Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA (mRNA) vaccines.

Precision NanoSystems provides technology that supports the development and manufacturing of lipid nanoparticles to help deliver genetic medicines, including mRNA vaccines. The companies cited the rapid growth of the mRNA segment as one of the reasons behind the deal.

Precision NanoSystems will join Danaher's life sciences platform and will complement other Danaher subsidiaries including Cytiva and Pall. Precision NanoSystems will continue to develop a new manufacturing center in Vancouver as planned.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?